[[(2R,3R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,4S,5R)-3,4-dimethoxy-5-(2-methyl-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - （5'->5'）-二核苷酸
• 英文名称: [[(2R,3R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,4S,5R)-3,4-dimethoxy-5-(2-methyl-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
• 化学式: C24H35N9O18P3+
• 分子量: 830.5
• InChiKey: VRFZXEIOYXDHRF-XTPXSXIBSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -7.1
• 重原子数：
  54
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  362
• 氢给体数：
  8
• 氢受体数：
  19

文献信息

• TERMINALLY MODIFIED RNA
  申请人：Chakraborty Tirtha

  公开号：US20140147454A1

  公开（公告）日：2014-05-29

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
• ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20170175129A1

  公开（公告）日：2017-06-22

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.
• US9597380B2
  申请人：——

  公开号：US9597380B2

  公开（公告）日：2017-03-21